Urologic Oncology: Seminars and Original Investigations
Original articleRoutine bladder cancer treatment dictates divergence from trial-derived regimens: Results of treatment at 44 radiotherapy centers
Introduction
Bladder-preserving trimodality chemoradiotherapy (CRT) is accepted as a first-line option in Europe [1], [2] and elsewhere since, compared to cystectomy it yields similar survival [3], [4], [5] and possibly improved outcome [6]. Only recently has it been included as a choice in the National Comprehensive Cancer Network Guidelines [7]. Instead, in the United States, it is common practice to offer definitive surgery to fit patients. Most of the data for CRT in the United States emerges from a few large academic centers [8] and Radiation Therapy Oncology Group (RTOG) trials. With the small volume of cases at most academic centers in the United States, the exposure of residents in training to this procedure may be limited, yet when practicing out in the community, radiation oncologists need to perform bladder CRT. We, therefore, examined the characteristics and outcome of patients who were treated for muscle-invasive bladder cancer (MIBC) at 44 community-based 21st Century Oncology radiotherapy (RT) centers in the United States and compared these to a pooled analysis of CRT from 6 RTOG protocols [9]. The incidence of treatment of this disease will continue to increase as life expectancy increases in developed countries [10] and as smoking becomes more prevalent in developing countries [11]. In 2012 an estimated 429,800 new cases of bladder cancer occurred worldwide [12].
Section snippets
Study type
We, retrospectively, reviewed the characteristics and outcome of patients with MIBC who were treated with RT at 44 centers that shared a single registry after ethical Institutional Review Board approval. The registry is a cancer registry that is used to report cases to each state within the United States. It is a comprehensive database that collects up to 815 fields of data that may be required by individual states in accordance with standards of the North American Association of Central Cancer
Comparison of patients against those on RTOG trials
There were 155 patients from August 2010 to June 2014 treated with RT whose characteristics listed in Table 1 alongside the respective values for patients of the RTOG pooled analysis.11 What is striking about the values in this table is that 51.0% were unfit for surgery in our study vs. 0% in RTOG (P<0.001); patients in the current study were older (P<0.0001), were more racially heterogeneous (P<0.0001), had poorer PS or more likely to be undocumented PS (P<0.0001), had less visibly complete
Practice of bladder chemoradiation outside of clinical trials
The 36-month OS for concurrent CT patients who refused surgery (66.3%) is comparable to the RTOG results. This reflects good performance of bladder CRT in community-based centers outside the academic setting. These results are respectable, especially given the high percentage of patients without a complete TURBT, a known adverse prognostic feature. It raises the question of the effect of major technological difference between this series and the techniques used in the patients of the pooled
Conclusions
Despite poorer patient characteristics, the 36-month OS of 66.3% for patients who refused surgery and received CRT is encouraging. It suggests that it is appropriate to offer bladder CRT in community free-standing centers. This good outcome may be related to improvement in techniques for planning and delivery of RT. The promising 36-month OS of 38.9% for patients who were unfit for surgery and received CRT suggests that patients with medical comorbidity should be considered for CRT instead of
Acknowledgment
We wish to thank April Mann, Writing Center Director, Senior Lecturer, College of Arts and Sciences, Department of English, University of Miami for her painstaking guidance in writing this article.
Presentations
An abstract of this article in part was published at the Annual Meeting of the American Society of Clinical Oncology 2017.
An abstract of this article in part was presented at the Annual Meeting of the American Society of Radiation Oncology, Boston MA, USA, 2016.
References (32)
- et al.
Radical cystectomy versus bladder-preserving therapy for muscle invasive urothelial carcinoma: examining confounding and misclassification bias in cancer observational comparative effectiveness research
Value Health
(2013) - et al.
Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study
Clin Oncol (R Coll Radiol)
(2014) - et al.
Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: a systematic review of clinical trials
Crit Rev Oncol Hematol
(2015) - et al.
Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer
Urology
(2002) Appraisal of methods for the study of chemotherapy in man: Comparative therapeutic trial of nitrogen mustard and thiophosphoramide
J Chronic Dis
(1960)- et al.
Interconversion of three measures of performance status: an empirical analysis
Eur J Cancer
(2010) - et al.
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
Int J Radiat Oncol Biol Phys
(1995) - et al.
Members of the IMRT indications expert panel. Intensity-modulated radiotherapy in the treatment of prostate cancer
Clin Oncol (R Coll Radiol)
(2012) - et al.
Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience
Eur Urol
(2012) - et al.
Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial
Int J Radiat Oncol Biol Phys
(2009)
Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: a pooled individual data analysis of eight phase I-II trials
Radiother Oncol
A simulation study of the number of events per variable in logistic regression analysis
J Clin Epidemiol
Ageing populations: the challenges ahead
Lancet
Cancer and aging. An evolving panorama
Hematol Oncol Clin North Am
Clinical outcomes with dose-escalated adaptive radiation therapy for urinary bladder cancer: a prospective study
Int J Radiat Oncol Biol Phys
Prospective study delivering simultaneous integrated high-dose tumor boost (≤70 Gy) with image guided adaptive radiation therapy for radical treatment of localized muscle-invasive bladder cancer
Int J Radiat Oncol Biol Phys
Cited by (1)
- 1
The author has moved since this work described in this article was done.